National Cancer Institute (NCI): Kidney Neoplasms trials

The registry lists 61 Kidney Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 7 are open to participants now and 26 have results posted.

Early Phase 1 1Phase 1 19Phase 2 38Phase 3 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitingNCT06479811Phase 1
• Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingNCT05665361Phase 1/2
• Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesRecruitingNCT01109394
• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal CancerRecruitingNCT00050752
• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney CancerRecruitingNCT00033137
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruitingNCT00026884
• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedNCT04150562Phase 2Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveTerminatedNCT02153905Phase 1/2Results posted
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney CancersCompletedNCT02141490Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveCompletedNCT02111850Phase 1/2Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Imaging Studies of Kidney Cancer Using 18F-VM4-037TerminatedNCT01712685Phase 2Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Vandetanib to Treat Advanced Kidney CancerTerminatedNCT01372813Phase 2Results posted
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered LymphocytesTerminatedNCT01273181Phase 1/2Results posted
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedNCT01239342Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic CancerTerminatedNCT01218867Phase 1/2Results posted
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerTerminatedNCT01160445Phase 2Results posted
• Phase II Study of Vandetanib in Individuals With Kidney CancerCompletedNCT00566995Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2Results posted
• Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the UrotheliumTerminatedNCT00363883Phase 2Results posted
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney CancerCompletedNCT00328861Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractCompletedNCT00112671Phase 2Results posted
• Vaccine Treatment of Kidney CancerTerminatedNCT00089778Phase 2Results posted
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau DiseaseCompletedNCT00088374Phase 2Results posted
• Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerCompletedNCT00069160Phase 2Results posted
• [18]F-Fluciclatide for Kidney Cancer Imaging Studies and TreatmentWithdrawnNCT01633255Phase 1/2
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerTerminatedNCT01457131Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal CancersTerminatedNCT01086696Early Phase 1
• Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 ReceptorTerminatedNCT00923390Phase 1
• Follow-Up Study of Kidney Cancer PatientsCompletedNCT00656955
• Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United StatesCompletedNCT00340457
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00301847Phase 2
• Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerTerminatedNCT00091611Phase 1
• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder CancerCompletedNCT00041106Phase 2
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00020540Phase 1
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00019955Phase 2
• Liposomal Doxorubicin in Treating Children With Refractory Solid TumorsCompletedNCT00019630Phase 1
• Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerCompletedNCT00005831Phase 2
• Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced CancerTerminatedNCT00005655Phase 1
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Bryostatin 1 in Treating Patients With Metastatic Kidney CancerCompletedNCT00003968Phase 2
• Lymphocyte Therapy in Treating Patients With Kidney CancerStatus unknownNCT00002589Phase 2
• Von Hippel-Lindau Disease Genetic Epidemiology StudyTerminatedNCT00001803
• A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal CancerCompletedNCT00001570Phase 1
• A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833CompletedNCT00001302Phase 1